Want to see HK:2877 full AI Analyst Report?
China Shineway Pharmaceutical Group Limited (2877) Ratios
China Shineway Pharmaceutical Group Limited Ratios
HK:2877's free cash flow for Q2 2026 was $296.24M. For the 2026 fiscal year, HK:2877's free cash flow was decreased by $-77.45M and operating cash flow was $373.69M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.71 | 3.51 | 3.35 | 4.07 | 5.19 |
| Quick Ratio | 3.43 | 3.18 | 2.98 | 3.68 | 4.65 |
| Cash Ratio | 2.86 | 2.51 | 2.42 | 3.02 | 3.83 |
| Solvency Ratio | 0.38 | 0.39 | 0.45 | 0.49 | 0.57 |
| Operating Cash Flow Ratio | 0.47 | 0.39 | 0.38 | 0.67 | 0.64 |
| Short-Term Operating Cash Flow Coverage | 3.61 | 2.92 | 3.11 | 0.00 | 0.00 |
| Net Current Asset Value | $ 6.59B | $ 6.02B | $ 5.62B | $ 4.93B | $ 4.40B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.04 | 0.05 | 0.04 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.04 | 0.04 | 0.04 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.34 | 1.34 | 1.36 | 1.29 | 1.22 |
| Debt Service Coverage Ratio | 1.31 | 2.07 | 3.80 | 1443.28 | 590.36 |
| Interest Coverage Ratio | 119.98 | 137.48 | 356.42 | 1132.66 | 426.13 |
| Debt to Market Cap | 0.06 | 0.05 | 0.06 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.45 | 0.47 | 0.40 | 0.01 | 0.02 |
| Net Debt to EBITDA | -9.11 | -5.78 | -3.93 | -4.55 | -4.64 |
| Profitability Margins | |||||
| Gross Profit Margin | 72.28% | 74.95% | 75.15% | 74.38% | 74.77% |
| EBIT Margin | 21.75% | 22.13% | 27.52% | 23.23% | 22.38% |
| EBITDA Margin | 24.01% | 26.52% | 31.44% | 27.93% | 28.04% |
| Operating Profit Margin | 21.75% | 22.30% | 21.60% | 18.06% | 16.58% |
| Pretax Profit Margin | 40.48% | 30.33% | 27.46% | 23.21% | 22.34% |
| Net Profit Margin | 30.30% | 22.24% | 21.47% | 18.30% | 17.27% |
| Continuous Operations Profit Margin | 30.30% | 22.24% | 21.47% | 18.30% | 17.27% |
| Net Income Per EBT | 74.84% | 73.32% | 78.17% | 78.82% | 77.30% |
| EBT Per EBIT | 186.09% | 135.97% | 127.14% | 128.51% | 134.76% |
| Return on Assets (ROA) | 8.81% | 8.37% | 10.13% | 8.78% | 7.73% |
| Return on Equity (ROE) | 11.78% | 11.25% | 13.78% | 11.32% | 9.43% |
| Return on Capital Employed (ROCE) | 8.25% | 11.10% | 13.66% | 10.87% | 8.75% |
| Return on Invested Capital (ROIC) | 5.93% | 7.79% | 10.25% | 8.58% | 6.78% |
| Return on Tangible Assets | 8.96% | 8.53% | 10.34% | 9.01% | 7.98% |
| Earnings Yield | 16.28% | 12.25% | 19.12% | 14.28% | 13.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.06 | 3.14 | 3.58 | 4.05 | 3.91 |
| Payables Turnover | 2.56 | 2.35 | 2.32 | 3.28 | 3.56 |
| Inventory Turnover | 1.26 | 1.16 | 1.25 | 1.54 | 1.38 |
| Fixed Asset Turnover | 2.51 | 3.10 | 3.75 | 3.25 | 2.57 |
| Asset Turnover | 0.29 | 0.38 | 0.47 | 0.48 | 0.45 |
| Working Capital Turnover Ratio | 0.48 | 0.64 | 0.83 | 0.81 | 0.72 |
| Cash Conversion Cycle | 266.73 | 274.34 | 236.13 | 215.89 | 254.72 |
| Days of Sales Outstanding | 119.17 | 116.11 | 101.86 | 90.09 | 93.43 |
| Days of Inventory Outstanding | 290.41 | 313.66 | 291.93 | 237.12 | 263.90 |
| Days of Payables Outstanding | 142.84 | 155.43 | 157.65 | 111.32 | 102.61 |
| Operating Cycle | 409.58 | 429.77 | 393.78 | 327.21 | 357.33 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.55 | 1.27 | 1.23 | 1.47 | 0.93 |
| Free Cash Flow Per Share | 1.29 | 1.09 | 1.04 | 1.30 | 0.81 |
| Dividend Paid and CapEx Coverage Ratio | 2.12 | 1.76 | 2.02 | 2.99 | 1.29 |
| Capital Expenditure Coverage Ratio | 5.92 | 6.87 | 6.46 | 8.57 | 7.51 |
| Operating Cash Flow Coverage Ratio | 3.50 | 2.78 | 3.10 | 149.11 | 47.16 |
| Operating Cash Flow to Sales Ratio | 0.37 | 0.25 | 0.21 | 0.28 | 0.22 |
| Free Cash Flow Yield | 16.69% | 12.00% | 15.54% | 19.36% | 14.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 6.13 | 8.17 | 5.23 | 7.00 | 7.61 |
| Price-to-Sales (P/S) Ratio | 1.86 | 1.82 | 1.12 | 1.28 | 1.31 |
| Price-to-Book (P/B) Ratio | 0.72 | 0.92 | 0.72 | 0.79 | 0.72 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 5.99 | 8.33 | 6.43 | 5.16 | 6.95 |
| Price-to-Operating Cash Flow Ratio | 4.98 | 7.12 | 5.44 | 4.56 | 6.03 |
| Price-to-Earnings Growth (PEG) Ratio | 0.45 | -0.61 | 0.16 | 0.24 | 0.08 |
| Enterprise Value Multiple | -1.36 | 1.06 | -0.36 | 0.04 | 0.05 |
| Enterprise Value | -1.02B | 1.07B | -515.64M | 43.85M | 46.45M |
| EV to EBITDA | -1.36 | 1.06 | -0.36 | 0.04 | 0.05 |
| EV to Sales | -0.33 | 0.28 | -0.11 | 0.01 | 0.01 |
| EV to Free Cash Flow | -1.05 | 1.29 | -0.65 | 0.04 | 0.08 |
| EV to Operating Cash Flow | -0.87 | 1.11 | -0.55 | 0.04 | 0.07 |
| Tangible Book Value Per Share | 10.44 | 9.62 | 9.03 | 8.17 | 7.51 |
| Shareholders’ Equity Per Share | 10.68 | 9.87 | 9.29 | 8.45 | 7.82 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | 0.27 | 0.22 | 0.21 | 0.23 |
| Revenue Per Share | 4.15 | 4.99 | 5.96 | 5.23 | 4.27 |
| Net Income Per Share | 1.26 | 1.11 | 1.28 | 0.96 | 0.74 |
| Tax Burden | 0.75 | 0.73 | 0.78 | 0.79 | 0.77 |
| Interest Burden | 1.86 | 1.37 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 |
| SG&A to Revenue | 0.46 | 0.50 | 0.07 | 0.07 | 0.08 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.92 | 0.84 | 0.75 | 1.54 | 1.26 |
Currency in CNY
